ETNB vs. AMLX, MRUS, XNCR, ANIP, OPK, BHVN, KNSA, AUPH, SAGE, and DAWN
Should you be buying 89bio stock or one of its competitors? The main competitors of 89bio include Amylyx Pharmaceuticals (AMLX), Merus (MRUS), Xencor (XNCR), ANI Pharmaceuticals (ANIP), OPKO Health (OPK), Biohaven (BHVN), Kiniksa Pharmaceuticals (KNSA), Aurinia Pharmaceuticals (AUPH), Sage Therapeutics (SAGE), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical preparations" industry.
89bio vs.
89bio (NASDAQ:ETNB) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation.
89bio has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.93, indicating that its share price is 193% less volatile than the S&P 500.
89bio currently has a consensus price target of $37.44, indicating a potential upside of 145.86%. Amylyx Pharmaceuticals has a consensus price target of $49.40, indicating a potential upside of 163.89%. Given Amylyx Pharmaceuticals' higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than 89bio.
89bio has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.
89bio received 65 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. However, 72.00% of users gave Amylyx Pharmaceuticals an outperform vote while only 61.48% of users gave 89bio an outperform vote.
89bio has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -37.95%. Amylyx Pharmaceuticals' return on equity of -23.80% beat 89bio's return on equity.
87.7% of Amylyx Pharmaceuticals shares are owned by institutional investors. 4.4% of 89bio shares are owned by insiders. Comparatively, 11.8% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, 89bio had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 9 mentions for 89bio and 2 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.75 beat 89bio's score of 0.44 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.
Summary
Amylyx Pharmaceuticals beats 89bio on 9 of the 16 factors compared between the two stocks.
Get 89bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
